Devonian Health Group

Devonian Health Group Inc. is a publicly traded, late-stage botanical pharmaceutical company established in 2015 and headquartered in Québec, Canada. The company was founded by Dr. André P. Boulet, who brings extensive experience in drug development, regulatory affairs, and finance from his time at pharmaceutical giants like Sanofi and venture capital firms. His background in both science—holding a PhD in physiology-endocrinology—and finance has been instrumental in raising over $50 million for the company. Devonian focuses on developing prescription botanical drugs for inflammatory and autoimmune diseases, leveraging a U.S. FDA regulatory pathway that can be more efficient for plant-based medicines. This strategy is built on more than fifteen years of research and a proprietary technology platform, SUPREX™, for extracting and stabilizing active ingredients from plants.

The company's core business involves two main streams: the development of its proprietary drug candidates and the distribution of existing pharmaceutical products. Its primary drug candidate is Thykamine™, a multi-target anti-inflammatory and anti-oxidative agent derived from its SUPREX™ platform. Thykamine™ has completed Phase 2 clinical trials for treating mild-to-moderate atopic dermatitis and ulcerative colitis. Recent preclinical studies have also shown its potential in treating metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Revenue is primarily generated through its wholly-owned subsidiary, Altius Healthcare Inc., acquired in 2018. Altius markets and distributes branded and generic medicines in Canada, including the authorized generic DEXLANSOPRAZOLE for gastroesophageal reflux disease (GERD), which significantly boosted revenues in fiscal year 2024. This dual approach allows Devonian to generate cash flow to support its long-term, capital-intensive R&D pipeline. The company also develops and markets cosmeceutical products, such as the Purgenesis anti-aging line, leveraging the same botanical technology.

Devonian is listed on the TSX Venture Exchange (GSD) and the OTCQB market (DVHGF). The company's financial results for the fiscal year ending July 31, 2024, showed a significant increase in annual revenues to $17.8 million, largely driven by the sales from its Altius division. While navigating the transition from a high-growth phase to sustainable profitability, the firm continues to advance Thykamine™ through the clinical trial process, with plans for Phase 3 trials and expansion into pediatric patient populations.

Keywords: botanical pharmaceuticals, Thykamine, atopic dermatitis treatment, ulcerative colitis therapy, autoimmune diseases, inflammatory diseases, Altius Healthcare, SUPREX platform, cosmeceuticals, prescription botanical drugs, drug development, clinical-stage company, pharmaceutical distribution, André P. Boulet, MASH treatment, anti-inflammatory drugs, generic pharmaceuticals, dermatology, gastroenterology, metabolic liver disease, plant-based medicine, Purgenesis, pharmaceutical research